Stevens Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Stevens Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14,796	Closed	-$225K	–	1028
2018 Q3	$225K	Sell	14,796 -1,869	-11%	-$28.6K	0.01%	633
2018 Q2	$280K	Buy	+16,665	New	+$265K	0.01%	641
2016 Q1	–	Sell	-40,164	Closed	-$169K	–	1202
2015 Q4	$169K	Sell	40,164 -97,271	-71%	-$444K	0.01%	822
2015 Q3	$627K	Buy	137,435 +18,901	+16%	+$112K	0.03%	468
2015 Q2	$855K	Buy	118,534 +64,542	+120%	+$476K	0.03%	461
2015 Q1	$398K	Buy	53,992 +21,055	+64%	+$150K	0.01%	642
2014 Q4	$156K	Buy	+32,937	New	+$130K	0.01%	891
2013 Q3	–	Sell	-12,867	Closed	-$58K	–	1278
2013 Q2	$58K	Buy	+12,867	New	+$69.2K	﹤0.01%	881

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Stevens Capital Management's ARRY Position: Q4 2018 in Review

Stevens Capital Management sold out of Array Biopharma Inc (ARRY) in Q4 2018, closing a stake of 14,796 shares — an estimated $225K sold.

Stevens Capital Management first reported a position in ARRY in Q2 2013 and held it in 8 quarters. The position peaked at $855K in Q2 2015. 236 funds tracked by Wall St. Rank hold ARRY as of Q4 2018.

Stevens Capital Management reported no remaining Array Biopharma Inc position as of Q4 2018 after selling out during the quarter.
Stevens Capital Management sold 14,796 Array Biopharma Inc shares in Q4 2018, an estimated $225K.
Stevens Capital Management first reported a position in Array Biopharma Inc in Q2 2013 and held it in 8 quarters.
Stevens Capital Management's Array Biopharma Inc position peaked at $855K in Q2 2015.
236 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2018.

Based on Stevens Capital Management's 13F filing for Q4 2018, filed 6 Feb 2019.